Updates are available Correction dated 2023-04-14
Click to view Correction: https://doi.org/10.1186/s40780-023-00284-z
-
Authors
Tsuboi, Shinya
Hayama, Tatsuya
Miura, Katsuhiro http://orcid.org/0000-0002-1538-3804
Uchiike, Akihiro
Tsutsumi, Daisuke
Yamauchi, Takashi
Hatta, Yoshihiro
Ootsuka, Susumu
- License Information
-
More Information
Article History
Received: 19 October 2022
Accepted: 26 December 2022
First Online: 10 January 2023
Change Date: 14 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40780-023-00284-z
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki. All patients provided informed consent for chemotherapy and supportive therapies, including prophylaxis for FN using pegfilgrastim. The Nihon University Itabashi Hospital Clinical Research Judging Committee approved the data collection, analysis, and publication of this study on July 11, 2018 (RK-180710–17).
: Consent for publication was not required owing to the retrospective nature of the study.
: Katsuhiro Miura received speaker fees from Kyowa-Kirin, which manufactures pegfilgrastim in Japan.
